Purpose:
To evaluate transarterial chemoembolization (TACE) use prior to and concomitantly with sorafenib in patients with unresectable hepatocellular carcinoma (HCC) across different global regions.
Materials and Methods:
GIDEON is an observational registry study of more than 3000 HCC patients. Patients with histologically, cytologically, or radiographically diagnosed HCC, and for whom a decision had been made to treat with sorafenib, were eligible. Patients were enrolled into the registry from 39 countries beginning in January 2009, with the last patient follow-up in April 2012. Detailed data on treatment history, treatment patterns, adverse events, and outcomes were collected. All treatment decisions were at the discretion of the treating physicians. Documented approval from local ethics committees was obtained, and all patients provided signed informed consent. Descriptive statistics, including minimum, median, and maximum, were calculated for metric data, and frequency tables for categorical data. Kaplan-Meier estimates with 95% confidence intervals were calculated for survival end points.
Results:
A total of 3202 patients were eligible for safety analysis, of whom 2631 (82.2%) were male. Median age was 62 years (range, 15-98 years). A total of 1511 (47.2%) patients underwent TACE prior to sorafenib; 325 (10.1%) underwent TACE concomitantly. TACE prior to sorafenib was more common in Japan and Asia-Pacific compared with all other regions (362 [71.3%] and 560 [60.3%] vs 12-209 [13.3%-37.1%]). Adverse events were reported in 2732 (85.3%) patients overall, with no notable differences in the incidence of adverse events, regardless of TACE treatment history. Overall survival was 12.7 months in prior-TACE patients, 9.2 months in non-prior-TACE patients, 21.6 months in concomitant-TACE patients, and 9.7 months in non-concomitant-TACE patients.
Conclusion:
Global variation exists in TACE use in sorafenib-treated HCC patients. The combination of TACE with sorafenib appears to be a well-tolerated and viable therapeutic approach.
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use and associated safety and outcomes in a clinical practice setting. The GIDE-ON study began enrolling patients in 2009 and was completed in 2012, with more than 3000 sorafenib-treated patients enrolled from 39 countries in five global regions. Findings from two interim analyses have been previously reported in approximately 500 and 1500 patients (21, 22) . Here, we report data from the final analyses of GIDEON.
Materials and Methods
The GIDEON study is sponsored by Bayer Healthcare Pharmaceuticals and Onyx Pharmaceuticals, an Amgen subsidiary. J.A.M., R.L., M.K., S.L.Y., and A.P.V. are members of the Global Steering and Publication Committee for the GIDEON study; they were involved in the development of the GIDEON protocol and in data review and interpretation. J.A.M., R.L., M.K., S.L.Y., A.P.V., J.P.B., X.P.C., L.D., J.F., J.F.H.G., L.L.d.G., C.P., A.J.S., T.T., and S.K.Y. were responsible for the provision of patients and data acquisition. K.N., R.L., and S.H. are employees of Bayer invasion or extrahepatic spread (4) (5) (6) . Sorafenib (Nexavar; Bayer Pharma, Berlin, Germany) is an oral multikinase inhibitor with antiangiogenic activity and is the only approved systemic treatment for advanced HCC (6) . Sorafenib is recommended as a first-line therapy for patients with extensive disease; with confirmed metastasis; who cannot benefit from resection, transplantation, or additional local-regional therapies (LRTs); and who have preserved liver function (6) . Currently, TACE and sorafenib are the only noncurative treatments for advanced HCC that have been shown to provide a survival benefit in HCC patients (7) (8) (9) .
While TACE is widely used in the management of HCC, there is no single, globally accepted therapeutic algorithm for TACE use or for assessment of the response to TACE in clinical practice (10) , although scoring systems have been recently developed to inform TACE initiation (selection for transarterial chemoembolization treatment, or STATE) and retreatment (assessment for re-treatment with TACE, or ART) (11,12). However, not all patients who undergo TACE derive clinical benefit, and patients may experience tumor recurrence (13,14). Recurrence may occur because of the proangiogenic effects of hypoxia resulting from TACE-induced necrosis at the tumor site (13). The antiangiogenic effect of sorafenib has the potential to synergistically offset this effect of TACE, and multiple trials have shown promising safety and efficacy data on the use of TACE combined with sorafenib in HCC patients (15-19).
Global investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib (GIDEON) is a nonrandomized observational registry study undertaken to evaluate the safety of sorafenib in patients with unresectable HCC in clinical practice (20) . The GIDEON study design allowed for the collection of a large, robust, and clinically relevant global dataset, with a preplanned range of subanalyses across patient subgroups. Data on the use of TACE prior to or concomitantly with sorafenib were collected to allow assessment of TACE and sorafenib 
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Results
Patient Disposition
Overall, 3202 patients were eligible for and included in the safety analysis (Fig 1) .
Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0 (National Cancer Institute, Bethesda, Md), and the likely relationship of sorafenib to any adverse event was documented as part of the case report form. Patients who received at least one dose of sorafenib and underwent at least one follow-up examination were evaluable for safety. The primary objective of GIDEON was to evaluate the safety of sorafenib in patients with HCC under real-life practice conditions. Secondary objectives included evaluating sorafenib efficacy, duration of therapy, and treatment practice across various clinically relevant subsets of patients. Full details of the GIDEON study design and rationale have previously been published (20).
Enrollment was planned for 3000 patients, which was deemed sufficient Healthcare and were the lead medical advisor, internal statistician, and global study manager, respectively. All authors had access to relevant data and had control of which data were included in the manuscript. The final decision on manuscript content rested with the authors who are not Bayer employees. The GIDEON protocol is available at https:// www.clinicaltrials.gov/ct2/show/NCT0 0812175?term=NCT00812175&rank=1, and a synopsis of the study results is publicly available at http://pharma.bayer.com/en/research-and-development/. The required documented approval from the appropriate ethics committees and institutional review boards was obtained for all participating centers prior to the study. All patients provided signed, informed consent to be included in the registry. The GIDEON study began enrolling patients in January 2009 and was completed in April 2012.
Patients with a histologic, cytologic, or radiographic diagnosis of unresectable HCC and with a life expectancy of more than 8 weeks were included in the GIDEON study. Exclusion criteria were based on locally approved product information for sorafenib.
Comprehensive case report forms were used to collect patient data. Information on demographics, baseline disease characteristics, previous therapies, and initial sorafenib dose was recorded at the patients' initial visits. Subsequent follow-up visits were at the discretion of the treating physicians, during which data regarding sorafenib dose (including any modifications or discontinuation), concomitant treatments, adverse events, and outcomes (including death) were collected. The independent contract research organization Kantar Health (Munich, Germany) was responsible for data capture, data management, data quality review, and statistical reporting, overseen by Bayer Healthcare Pharmaceuticals.
All treatment decisions, including the administration of treatments concomitantly with sorafenib, were determined entirely at the discretion of the treating physicians. As such, the type, schedule, and other aspects of TACE were not dictated by the study protocol. 
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Use of Prior and Concomitant Therapies
In total, 57.5% of patients had received LRT prior to study entry, although with regional variation. Overall, TACE was the most common prior LRT received ( 
Sorafenib Administration
The median daily dose of sorafenib was lower in patients previously treated with TACE compared with those who had not been previously treated with TACE (603.0 mg vs 757.0 mg) ( Table 3) . The median daily dose of sorafenib was also lower in concomitantly treated TACE patients compared with nonconcomitantly treated patients (587.0 mg vs 698.5 mg). The overall median duration of sorafenib therapy was 15.0 weeks, although it was notably longer radiation being the most frequent (2.6%) ( Table 1) . A small number of patients underwent TACE after sorafenib discontinuation (4.3%), most commonly in Japan (11.8%) ( (Fig 3a, 3b) . Overall survival was longer in concomitantly treated patients across Barcelona Clinic Liver Cancer stages (Fig 4) .
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Discussion
The large database generated from systematic data collection in GIDEON offers an opportunity to assess global patterns of LRT use in the treatment of HCC in clinical practice. Final analyses of GIDEON highlighted that almost half of patients received TACE treatment in which approximately one-third of patients had received TACE treatment prior to sorafenib (8) . A number of patients who received prior TACE treatment continued TACE treatment concomitantly with sorafenib, while some patients received TACE treatment only concomitantly with sorafenib. Therefore, GIDEON confirms that TACE combined with sorafenib is used in clinical practice, and more than 300 patients received this combination. The patterns of TACE use prior to sorafenib varied regionally, consistent with previous reports, particularly in the frequency of
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of TACE treatment practices and the publication of evidence-based guidelines to inform clinical decisions. Moreover, outcomes of HCC patients treated with TACE followed or not followed by sorafenib and the influence of timing to initiate sorafenib, or OPTIMIS, is an ongoing, prospective, observational study that will further evaluate the use of TACE and sorafenib in clinical practice.
Because GIDEON is an observational registry study, it is inherently limited by the lack of a randomized, controlled population. In addition, its observational nature means the study is also limited by the potential for selection bias and an inability to control for possible confounding factors. As such, it cannot evaluate if sorafenib in combination with TACE provided a benefit over TACE alone, and the descriptive statistics used do not allow for conclusive analysis of outcomes, so outcomes data must be interpreted with caution. However, GIDEON provides an opportunity to evaluate and understand global treatment patterns in clinical practice for the treatment of unresectable HCC. These data can be used to inform best practice and, ultimately, improve patient treatment and outcomes.
In conclusion, the findings from GIDEON in more than 3000 sorafenibtreated HCC patients highlight that global variation exists in LRT use for the treatment of HCC and in the technical aspects of TACE. Importantly, no safety concerns were noted in the use of TACE treatment either prior to or concomitant with sorafenib treatment. Therefore, TACE treatment prior to and/or concomitant with sorafenib appears to be a viable therapeutic approach in the treatment of unresectable HCC.
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Lipiodol-based TACE was the predominant choice and more common than DEB TACE, perhaps unsurprisingly as DEB is a relatively new method (13,24); for example, DEB TACE was not approved by the China Food and Drug Administration to be the choice of TACE agent except for use in clinical trials. DEB TACE use varied globally and was more common in Western regions. These data may reflect regional variations or delays in the uptake of DEB TACE, and patterns may alter as further safety and efficacy data in representative patient populations are reported (25) (26) (27) .
With respect to disease characteristics, patients without a history of TACE treatment tended to be at a more advanced stage of disease, likely reflecting that patients with an earlier disease stage may be more likely to receive TACE treatment. Some patients receiving concomitant TACE treatment had extrahepatic spread (28%) or vascular invasion (16%), somewhat contrary to TACE treatment guidelines, which recommend TACE use in intermediate noninvasive HCC (28) .
Safety findings in GIDEON were consistent with the known safety profile of sorafenib. There was no evidence of unanticipated adverse events or adverse event patterns in TACE-treated patients, and safety was similar in patients treated with TACE and those never treated with TACE. The combination of TACE with sorafenib appeared to be well tolerated, and safety profiles were broadly similar irrespective of the pattern of TACE use. Sorafenib administration data revealed that duration of sorafenib treatment was longest in patients who received concomitant TACE treatment (over 36 weeks), highlighting the feasibility of the combination.
Patients who received prior TACE treatment tended to have a slightly longer overall survival time compared with those who had not received prior TACE treatment. However, these outcomes data must be interpreted with caution, given the variations in disease characteristics between patients who received prior or concomitant TACE treatment and those never treated with TACE. Patients who underwent a combination of TACE with sorafenib had a longer overall survival compared with all other subgroups. However, data must be interpreted with caution as only a relatively low number of patients received concomitant TACE treatment compared with the other subgroups, and the majority of patients who received concomitant TACE treatment had also received TACE treatment prior to sorafenib.
A number of studies have reported that the combination of sorafenib and TACE resulted in improved overall survival in patients with advanced HCC (17, 19, 29, 30) . However, a further study reported no benefit of sorafenib when given sequentially to patients who had responded to TACE (31) . Ongoing trials will hopefully help to address key questions in relation to this combination in patients with advanced as well as intermediate stage HCC, including the optimal timing of sorafenib in relation to TACE and the influence of patient characteristics on the safety and efficacy of this combination (32) .
Overall, the final analysis of GIDE-ON highlights global variations in TACE treatment patterns, as observed in the previous interim analysis (21) . GIDEON data suggest that although prior TACE and TACE concomitant with sorafenib are tolerable and feasible, consistent with previous reports, variations exist in clinical practice, including the use of different TACE methodologies across global regions. GIDEON data may also reflect variations in decisions regarding when TACE should be performed and when TACE should be stopped (refractory), and thus when systemic therapy should be initiated (10) . Repeated courses of TACE with no objective response may detract from the administration of potentially effective systemic therapy as a result of a lack of evidencebased guidelines (33 
